Ann Lab Med.  2021 May;41(3):339-341. 10.3343/alm.2021.41.3.339.

Algorithm using Neuron-Specific Enolase and ProGastrin-Releasing Peptide to Increase the Diagnostic Accuracy for Small Cell Lung Cancer

• Lee H
• Park SD
• Kim T
• Kim J
• Jang TW
• Choi H
• Hwang H

• KMID: 2512695
• DOI: http://doi.org/10.3343/alm.2021.41.3.339

Figure

• 

  Fig. 1 Algorithm for differentiating between SCLC and NSCLC. The cutoff value for ProGRP is 85.70 pg/mL, and that for NSE is 17.30 ng/mL. When a discordant result is observed between ProGRP and NSE, two cutoff values are used. One of the values is 14.24 ng/mL, which is the cutoff value for 100% sensitivity of NSE based on the ROC curve analysis, and the other is 83.97 ng/mL, which is the mean value plus 3SD of NSE in the NSCLC patient group. We calculated these values based on the test results of 100 patients. Therefore, these values could be adjusted based on the evaluated patient groups in each institution. Abbreviations: NSE, neuron-specific enolase; ProGRP, pro-gastrinreleasing peptide; SCLC, small cell lung cancer.

Reference

1. Gazdar AF, Bunn PA, Minna JD. 2017; Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 17:725–37. DOI: 10.1038/nrc.2017.87. PMID: 29077690.

2. Yang S, Zhang Z, Wang Q. 2019; Emerging therapies for small cell lung cancer. J Hematol Oncol. 12:47. DOI: 10.1186/s13045-019-0736-3. PMID: 31046803. PMCID: PMC6498593.

3. Shen H. 2018; Low-dose CT for lung cancer screening: opportunities and challenges. Front Med. 12:116–21. DOI: 10.1007/s11684-017-0600-1. PMID: 29218678.

4. Isgrò MA, Bottoni P, Scatena R. 2015; Neuron-specific enolase as a biomarker: biochemical and clinical aspects. Adv Exp Med Biol. 867:125–43. DOI: 10.1007/978-94-017-7215-0_9. PMID: 26530364.

5. Nisman B, Biran H, Ramu N, Heching N, Barak V, Peretz T. 2009; The diagnostic and prognostic value of ProGRP in lung cancer. Anticancer Res. 29:4827–32. PMID: 20032442.

6. Kim HR, Oh IJ, Shin MG, Park JS, Choi HJ, Ban HJ, et al. 2011; Plasma pro GRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer. J Korean Med Sci. 26:625–30. DOI: 10.3346/jkms.2011.26.5.625. PMID: 21532852. PMCID: PMC3082113.

7. Korse CM, Holdenrieder S, Zhi XY, Zhang X, Qiu L, Geistanger A, et al. 2015; Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China. Clin Chim Acta. 438:388–95. DOI: 10.1016/j.cca.2014.09.015. PMID: 25262909.

8. Liu L, Teng J, Zhang L, Cong P, Yao Y, Sun G, et al. 2017; The combination of the tumor markers suggests the histological diagnosis of lung cancer. Biomed Res Int. 2017:2013989. DOI: 10.1155/2017/2013989. PMID: 28607926. PMCID: PMC5451759.

9. Oya Y, Yoshida T, Uemura T, Murakami Y, Inaba Y, Hida T. 2018; Serum Pro GRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer:A case report. Oncol Lett. 16:4219–22. DOI: 10.3892/ol.2018.9158. PMID: 30214557. PMCID: PMC6126188.

10. Yang DW, Zhang Y, Hong QY, Hu J, Li C, Pan BS, et al. 2015; Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients. Cancer. 121(S17):3113–21. DOI: 10.1002/cncr.29551. PMID: 26331818.